Skip to contentH
Haemonetics Corp
H
HAEHaemonetics Corp Q2 2019 · 10-Q
Revenue$241.58M$241.58M+7.2% vs Q2 2018 Net Income$18.73M$18.73M−6.8% vs Q2 2018 EPS Diluted$0.35$0.35−7.9% vs Q2 2018 Gross Profit$111,907,000+7.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Haemonetics Corp · CIK 313143 · Engraved from SEC EDGAR
Operating Cash Flowderived$57,357,000−2.6% Free Cash Flowderived$8,869,000−79.6% Margins · derivedGross margin46.3%−0.1 pt vs Q2 2018
Operating margin10.8%+0.0 pt vs Q2 2018
Net margin7.8%−1.2 pt vs Q2 2018
ended Sep 29, 2018 · filed Nov 6, 2018 · 38 d after period end